These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 22754543)

  • 1. Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs.
    Gohlke JM; Dhurandhar EJ; Correll CU; Morrato EH; Newcomer JW; Remington G; Nasrallah HA; Crystal S; Nicol G; ; Allison DB
    Front Psychiatry; 2012; 3():62. PubMed ID: 22754543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of antipsychotic medications on appetite, weight, and insulin resistance.
    Deng C
    Endocrinol Metab Clin North Am; 2013 Sep; 42(3):545-63. PubMed ID: 24011886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Mechanisms of Antipsychotic Drug-Induced Diabetes.
    Chen J; Huang XF; Shao R; Chen C; Deng C
    Front Neurosci; 2017; 11():643. PubMed ID: 29209160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
    Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
    Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management].
    Ruetsch O; Viala A; Bardou H; Martin P; Vacheron MN
    Encephale; 2005; 31(4 Pt 1):507-16. PubMed ID: 16389718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
    Newcomer JW
    CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The metabolic syndrome during atypical antipsychotic drug treatment: mechanisms and management.
    Baptista T; De Mendoza S; Beaulieu S; Bermúdez A; Martinez M
    Metab Syndr Relat Disord; 2004; 2(4):290-307. PubMed ID: 18370698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin for obesity and glucose dysregulation in patients with schizophrenia receiving antipsychotic drugs.
    Hasnain M; Fredrickson SK; Vieweg WV
    J Psychopharmacol; 2011 Jun; 25(6):715-21. PubMed ID: 21169390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychiatric drugs impact mitochondrial function in brain and other tissues.
    Chan ST; McCarthy MJ; Vawter MP
    Schizophr Res; 2020 Mar; 217():136-147. PubMed ID: 31744750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical models of antipsychotic drug-induced metabolic side effects.
    Boyda HN; Tse L; Procyshyn RM; Honer WG; Barr AM
    Trends Pharmacol Sci; 2010 Oct; 31(10):484-97. PubMed ID: 20674990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrinsic and Antipsychotic Drug-Induced Metabolic Dysfunction in Schizophrenia.
    Freyberg Z; Aslanoglou D; Shah R; Ballon JS
    Front Neurosci; 2017; 11():432. PubMed ID: 28804444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine D
    Wei H; Zapata RC; Lopez-Valencia M; Aslanoglou D; Farino ZJ; Benner V; Osborn O; Freyberg Z; McCarthy MJ
    Psychoneuroendocrinology; 2020 Mar; 113():104551. PubMed ID: 31884319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipsychotic induced weight gain in schizophrenia:mechanisms and management.
    Rege S
    Aust N Z J Psychiatry; 2008 May; 42(5):369-81. PubMed ID: 18473255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic risk during antipsychotic treatment.
    Newcomer JW
    Clin Ther; 2004 Dec; 26(12):1936-46. PubMed ID: 15823759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do neurotensin receptor agonists represent a novel class of antipsychotic drugs?
    Cáceda R; Kinkead B; Nemeroff CB
    Semin Clin Neuropsychiatry; 2003 Apr; 8(2):94-108. PubMed ID: 12728409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.
    Baptista T; Kin NM; Beaulieu S; de Baptista EA
    Pharmacopsychiatry; 2002 Nov; 35(6):205-19. PubMed ID: 12518268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic consequences of antipsychotic therapy: preclinical and clinical perspectives on diabetes, diabetic ketoacidosis, and obesity.
    Heal DJ; Gosden J; Jackson HC; Cheetham SC; Smith SL
    Handb Exp Pharmacol; 2012; (212):135-64. PubMed ID: 23129331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Schizophrenia, diabetes mellitus and antipsychotics].
    Gury C
    Encephale; 2004; 30(4):382-91. PubMed ID: 15538314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.